PRE-CLINICAL IMMUNE RESPONSE AND SAFETY EVALUATION OF THE PROTEIN SUBUNIT VACCINE NANOCOVAX FOR COVID-19

  1. Tran Thi Nhu Mai
  2. Bruce May
  3. Ung Trong Thuan
  4. Nguyen Mai Khoi
  5. Nguyen Thi Thuy Trang
  6. Dinh Van Long
  7. Doan Chinh Chung
  8. Tran The Vinh
  9. Khong Hiep
  10. Nguyen Thi Thanh Truc
  11. Hua Hoang Quoc Huy
  12. Nguyen Viet Anh
  13. Ha Tan Phat
  14. Phan Dang Luu
  15. Nguyen Truong An
  16. Bui Thi Ngoc
  17. Tu Tieu My
  18. Nguyen Thi Theo
  19. Le Thi Thuy Hang
  20. Dong Thi Lan
  21. Huynh Trong Hieu
  22. Ho Phien Huong
  23. Le Nguyen Thanh Thao
  24. Truong Cong Thao
  25. Pham Hoang Phi
  26. Y Luong Cong
  27. Nie Lim
  28. Cao Minh Ngoc
  29. Nguyen Duy Khanh
  30. Trinh Thanh Hung
  31. Do Minh Si
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

The Coronavirus disease-2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has become a dire global health concern. The development of vaccines with high immunogenicity and safety is crucial for control of the global COVID-19 pandemic and prevention of further illness and fatalities. Here, we report development of SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the S protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG, as well neutralizing antibody in three animal models including Balb/C mice, Syrian hamsters, and non-human primate (Macaca leonina). In addition, the viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. No adverse effects were induced by Nanocovax in swiss mice ( Musmusculus var. Albino), Rats (Rattus norvegicus), and New Zealand rabbits. These pre-clinical results indicated that Nanocovax is safe and effective.

Related articles

Related articles are currently not available for this article.